メチシリン耐性黄色ブドウ球菌(MRSA)感染症の疫学的予測

【英語タイトル】EpiCast Report: Methicillin-Resistant Staphylococcus Aureus (MRSA) - Epidemiology Forecast to 2024

GlobalDataが出版した調査資料(GDHCER097-15)・商品コード:GDHCER097-15
・発行会社(調査会社):GlobalData
・発行日:2015年10月13日
・ページ数:62
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD3,995 ⇒換算¥435,455見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD7,990 ⇒換算¥870,910見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD11,985 ⇒換算¥1,306,365見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、メチシリン耐性黄色ブドウ球菌(MRSA)感染症の疫学的市場予測について調査・分析し、以下の構成でお届けいたします。

・イントロダクション
・メチシリン耐性黄色ブドウ球菌(MRSA)感染症の概要
・リスク要因及び併存症
・主要地域の動向
・疫学的予測方法
・メチシリン耐性黄色ブドウ球菌(MRSA)感染症の疫学的予測結果(有病率など)
・考察(結論、分析の限界・強み)
【レポートの概要】

EpiCast Report: Methicillin-Resistant Staphylococcus Aureus (MRSA) – Epidemiology Forecast to 2024

Summary

The Staphylococcus aureus bacterium, which was discovered in the 1880s, is a common cause of painful skin and soft tissue infections (SSTIs). The discovery of penicillin in 1928 allowed for the routine and successful treatment of S. aureus infections. However, in the late 1940s and throughout the 1950s, S. aureus developed resistance to penicillin. Another form of penicillin, called methicillin, was introduced to counter the increasing problem of penicillin-resistant S. aureus. However, beginning in the 1960s, some strains of S. aureus began demonstrating resistance to methicillin, resulting in what is now known as methicillin-resistant Staphylococcus aureus (MRSA), which is resistant to all beta-lactam antibiotics, including penicillin, methicillin, and amoxicillin. Thus, MRSA has evolved from a controllable nuisance into a serious public health concern.

For this analysis, GlobalData epidemiologists defined MRSA as bacterial infections caused by methicillin-resistant S. aureus. These bacteria are resistant to beta-lactam antibiotics, such as methicillin, amoxicillin, penicillin, and oxacillin. This analysis only includes hospitalized MRSA cases arising from the following infections: pneumonia, SSTIs, and BSIs. The International Classification of Diseases, Tenth Revision (ICD-10), code for MRSA infections (unspecified site) is A49.02.

In 2014, there were a total of 797,883 hospitalized incident cases of MRSA in the 7MM. GlobalData epidemiologists forecast that the hospitalized incident cases of MRSA in the 7MM will increase to 884,727 cases by 2024 at an Annual Growth Rate (AGR) of 1.09%. The number of hospitalized incident cases of MRSA in the US, France, Italy, Spain, UK, and Japan will increase, with AGRs ranging from 0.14% (Italy) to 3.54% (Japan), but will decrease in Germany, with a negative AGR of 0.19%.

Scope

- The Methicillin-Resistant Staphylococcus aureus (MRSA) EpiCast Report provides an overview of the risk factors and global trends of MRSA in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). provides an overview of the risk factors, comorbidities, and the global and historical trends for MRSA in the 7MM and includes a 10-year epidemiological forecast for the hospitalized incident cases of MRSA, segmented by sex, age, infection site (pneumonias, SSTIs, and bloodstream infections [BSIs]), and case definition (HA-MRSA and CA-MRSA), in these markets.
- The MRSA epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The MRSA EpiCast series will allow you to –
- Develop business strategies by understanding the trends shaping and driving the global MRSA market.
- Quantify patient populations in the global MRSA market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MRSA therapeutics in each of the markets covered.
- Identify the percentage of MRSA hospitalized incident cases by infection site and case definition.

【レポートの目次】

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.3 Global Trends 12
3.3.1 US 12
3.3.2 5EU 13
3.3.3 Japan 13
3.4 Forecast Methodology 14
3.4.1 Sources Used 16
3.4.2 Sources Not Used 29
3.4.3 Forecast Assumptions and Methods 30
3.5 Epidemiological Forecast for MRSA (2014-2024) 38
3.5.1 Hospitalized Incident Cases of MRSA 38
3.5.2 Sex-Specific Hospitalized Incident Cases of MRSA 41
3.5.3 Age-Specific Hospitalized Incidence of MRSA 43
3.5.4 Age-Standardized Hospitalized Incidence Rate of MRSA 44
3.5.5 Proportion of Hospitalized Incident MRSA Cases by Infection Site 46
3.5.6 Proportion of Hospitalized Incident MRSA Cases by Case Definition 47
3.6 Discussion 48
3.6.1 Epidemiological Forecast Insight 48
3.6.2 Limitations of the Analysis 49
3.6.3 Strengths of the Analysis 49
4 Appendix 50
4.1 Bibliography 50
4.2 About the Authors 57
4.2.1 Epidemiologists 57
4.2.2 Reviewers 57
4.2.3 Global Director of Therapy Analysis and Epidemiology 58
4.2.4 Global Head of Healthcare 59
4.3 About GlobalData 60
4.4 About EpiCast 60
4.5 Disclaimer 61

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for MRSA 11
Table 2: Definitions of HA-MRSA and CA-MRSA 15
Table 3: US, Sources Used to Calculate the MRSA Incident Cases Arising from Pneumonias, SSTIs, and BSIs 17
Table 4: France, Sources Used to Calculate the MRSA Incident Cases Arising from Pneumonias, SSTIs, and BSIs 19
Table 5: Germany, Sources Used to Calculate the MRSA Incident Cases Arising from Pneumonias, SSTIs, and BSIs 21
Table 6: Italy, Sources Used to Calculate the MRSA Incident Cases Arising from Pneumonias, SSTIs, and BSIs 23
Table 7: Spain, Sources Used to Calculate the MRSA Incident Cases Arising from Pneumonias, SSTIs, and BSIs 25
Table 8: UK, Sources Used to Calculate the MRSA Incident Cases Arising from Pneumonias, SSTIs, and BSIs 27
Table 9: Japan, Sources Used to Calculate the MRSA Incident Cases Arising from Pneumonias, SSTIs, and BSIs 29
Table 10: 7MM, Hospitalized Incident Cases of MRSA, Men and Women, All Ages, N, 2014-2024 39
Table 11: 7MM, Sex-Specific Hospitalized Incident Cases of MRSA, All Ages, N, 2014 41
Table 12: 7MM, Age-Specific Hospitalized Incident Cases of MRSA, Men and Women, N, 2014 43

1.2 List of Figures
Figure 1: US, Methodology for Calculation of MRSA Hospitalized Incident Cases 33
Figure 2: 5EU, Methodology Used to Calculate the MRSA Hospitalized Incident Cases by Infection Type 37
Figure 3: 7MM, Hospitalized Incident Cases of MRSA, Men and Women, All Ages, N, 2014-2024 40
Figure 4: 7MM, Sex-Specific Hospitalized Incident Cases of MRSA, All Ages, N, 2014 42
Figure 5: 7MM, Age-Specific Hospitalized Incident Cases of MRSA, Men and Women, N, 2014 44
Figure 6: 7MM, Age-Standardized Hospitalized Incidence Rate of MRSA, 2014 45
Figure 7: 7MM, Proportion of Hospitalized Incident MRSA Cases by Infection Site, Men and Women, All Ages 46
Figure 8: 7MM, Proportion of Hospitalized Incident MRSA Cases by Case Definition, Men and Women, All Ages 47

【レポートのキーワード】

メチシリン耐性黄色ブドウ球菌(MRSA)感染症、疫学調査

★調査レポート[メチシリン耐性黄色ブドウ球菌(MRSA)感染症の疫学的予測] (コード:GDHCER097-15)販売に関する免責事項を必ずご確認ください。
★調査レポート[メチシリン耐性黄色ブドウ球菌(MRSA)感染症の疫学的予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆